Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific inhibitor of SGLT2(IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 38.00 | |
2 mg | In stock | $ 54.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 143.00 | |
25 mg | In stock | $ 273.00 | |
50 mg | In stock | $ 492.00 | |
100 mg | In stock | $ 688.00 | |
200 mg | In stock | $ 975.00 | |
500 mg | In stock | $ 1,430.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific inhibitor of SGLT2(IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2). |
Targets&IC50 | SGLT2 (rat):14.9 nM(Ki) , SGLT2:2.9 nM , SGLT2:6.4 nM(Ki), SGLT2 (human):2.9 nM(Ki) |
In vitro | Tofogliflozin, a highly selective inhibitor of SGLT2 on oxidative stress generation, inflammatory and proapoptotic reactions in cultured human proximal tubular cells exposed to high glucose.?Tofogliflozin dose-dependently suppressed glucose entry into tubular cells.?High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were suppressed by the treatment of tofogliflozin or an antioxidant N-acetylcysteine (NAC).?Monocyte chemoattractant protein-1 (MCP-1) gene expression and apoptotic cell death were induced by 4 h- and 8 day-exposure to high glucose, respectively, both of which were also blocked by tofogliflozin or NAC.?The present study suggests that SGLT2-mediated glucose entry into tubular cells could stimulate oxidative stress and evoke inflammatory and proapoptotic reactions in this cell type.?Blockade of glucose reabsorption in tubular cells by SGLT2 inhibitor might exert beneficial effects on tubulointerstitial damage in diabetic nephropathy[1]. |
Synonyms | Tofogliflozin hydrate, CSG-452 hydrate |
Molecular Weight | 404.45 |
Formula | C22H28O7 |
CAS No. | 1201913-82-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 0.33 mg/mL (0.82 mM), Sonification is recommended.
DMSO: 90 mg/mL (222.52 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tofogliflozin (hydrate) 1201913-82-7 GPCR/G Protein Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species ROS SGLT Tofogliflozin Hydrate inhibit CSG 452 Hydrate CSG 452 Inhibitor CSG452 CSG-452 CSG452 Hydrate Tofogliflozin Sodium-dependent glucose cotransporters CSG-452 Hydrate Tofogliflozin hydrate CSG-452 hydrate inhibitor